Source link : https://www.newshealth.biz/health-news/practice-changing-trial-for-inoperable-locally-advanced-nsclc/
CHICAGO — Patients without disease progression following chemoradiotherapy for unresectable stage III non-small cell lung cancer (NSCLC) should receive osimertinib (Tagrisso) if they harbor EGFR mutations, experts said here. In the randomized LAURA trial, median progression-free survival (PFS) increased seven-fold when patients received the EGFR inhibitor after definitive chemoradiation, improving from 5.6 months with placebo […]
Author : News Health
Publish date : 2024-06-02 18:00:00
Copyright for syndicated content belongs to the linked Source.
Categories